Related Experiment Video

Updated: May 1, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K

Hepatitis C protease and polymerase inhibitors in development

Gustine Liu-Young1, Michael J Kozal

  • 1Yale University School of Medicine, Department of Internal Medicine, Division of Infectious Diseases, 300 Cedar Street, S169, New Haven, Connecticut 06520, USA. gustine.liu-young@yale.edu

AIDS Patient Care and Stds
|May 16, 2008
PubMed

Insights

New Hepatitis C Virus (HCV) therapies targeting key viral enzymes show promise. These novel agents, including protease and polymerase inhibitors, are advancing to clinical trials for patients with limited treatment options.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C Virus (HCV) infection is a significant global health concern.
  • Current therapies offer limited efficacy, with sustained virologic response (SVR) rates around 50%, particularly for HCV genotype 1.
  • SVR rates are even lower in HIV-HCV co-infected patients (30-40%).

Purpose of the Study:

  • To review novel anti-HCV therapies currently in development.
  • To discuss agents targeting essential HCV enzymes like NS3 protease and NS5B polymerase.
  • To present early clinical trial data on efficacy, safety, and resistance profiles of new anti-HCV drugs.

Main Methods:

  • Focus on inhibitors of Hepatitis C Virus (HCV) NS3 protease and NS5B polymerase.
  • Identification of agents that have advanced to late-stage clinical trials.
  • Review of early trial results for efficacy, safety, and drug resistance.

Main Results:

  • Two protease inhibitors (telaprevir, boceprevir) and three polymerase inhibitors (valopicitabine, R1626, HCV-796) are in late-stage clinical trials.
  • Telaprevir is the most clinically advanced among these novel agents.
  • Early data on efficacy, safety, and resistance profiles are emerging for these compounds.

Conclusions:

  • Novel direct-acting antiviral agents targeting HCV enzymes represent a promising new therapeutic strategy.
  • These agents offer potential for improved SVR rates in patients with HCV, including those with prior treatment failures.
  • Further clinical evaluation is crucial to establish the role of these drugs in HCV management.

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

12.9K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58